Clinical trials: Metastatic Malignant Neoplasm to Brain
Breast Cancer, Brain Metastases
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain…
- Conditions
- Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT06088056
- Testing
- Combination use of SRT with T-DXd
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Fudan University
Metastases, Brain
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
- Trial name
- NCT00820222
- Testing
- capecitabine, lapatinib, trastuzumab
- Where
- 164 sites in United States, Belgium and 12 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Tumor, Brain, Meningioma of Brain
Sonography-guided Resection of Brain Mass Lesions
The study aims to perform a comparative analysis of preoperative CT/MRI and intraoperative ultrasound findings in patients with hemispheric brain tumors (meningiomas, gliomas, metastases), and to develop an intraoperative…
- Conditions
- Tumor, Brain, Meningioma of Brain, Glioma, Metastasis Brain
- Trial name
- SOMALI (NCT05484245)
- Testing
- Sonography
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
TNBC, Brain Metastasis
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases.
- Trial name
- NCT07623577
- Testing
- Sacituzumab Tirumotecan (Sac-TMT), bevacizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
This phase I trial studies the side effects of stereotactic radiosurgery with abemaciclib, ribociclib, or palbociclib in treating patients with hormone receptor positive breast cancer that has spread to the brain (brain…
- Conditions
- Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04585724
- Testing
- Abemaciclib, Palbociclib, Quality-of-Life Assessment
- Sponsor
- Emory University
Small Cell Lung Cancer Extensive Stage, Brain Metastases
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
- Conditions
- Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer
- Trial name
- PRISM (NCT07139990)
- Testing
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Brain Metastases
Evolution of Hypofractionated Stereotactic Irradiation for Radio-Resistant Brain Metastases From D1-3-5 to D1-2-3
The goal of this prospective, multi-center, randomized double-arm clinical trial is to demonstrate a benefit in term of local control of a shorter spread of hypofractionated stereotactic radiotherapy at D1-2-3 vs D1-3-5, in the…
- Trial name
- SISMIC (NCT07167134)
- Testing
- D1-3-5 radiotherapy, D1-2-3 radiotherapy
- Where
- France
- Volunteers
- 264 people
- Sponsor
- Centre Paul Strauss
Brain Cancer, Brain Metastases
Single vs Multi-fraction SRS Patients on Immunotherapy
This study is meant to compare different surgical approaches to brain cancer.
- Trial name
- MIGRAINE (NCT04427228)
- Testing
- Radiosurgery Single Treatment, Radiosurgery Three Treatments
- Where
- United States
- Sponsor
- University of Chicago
Neurocognitive Deficit, Quality of Life
WHOle Brain Irradiation or STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER)
This work aims to evaluate neurocognitive performance, daily activity and quality of life and local control among patients with brain metastasis (MBM) ≥ 5 due to solid tumors treated with Stereotactic RadioSurgery (SRS) or Whole…
- Conditions
- Neurocognitive Deficit, Quality of Life, Activities of Daily Living
- Trial name
- WHOBI-STER (NCT04891471)
- Testing
- Stereotactic RadioTherapy, Whole Brain Irradiation
- Where
- 4 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Mediterranean Institute of Oncology
Brain Metastases, Breast Cancer
Study Assessing QBS72S For Treating Brain Metastases
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
- Conditions
- Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease
- Trial name
- NCT05305365
- Testing
- QBS72S
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Melanie Hayden Gephart
Glioma, Brain Neoplasms
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant…
- Conditions
- Glioma, Brain Neoplasms, Brain Metastasis
- Trial name
- LevitraCarbo (NCT02279992)
- Testing
- Vardenafil, Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cedars-Sinai Medical Center
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Breast Cancer
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were…
- Trial name
- NCT04965064
- Testing
- Capecitabine and Neratinib.
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Rochester
Metastatic Melanoma, Metastasis to Brain
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal…
- Trial name
- NCT05704933
- Testing
- Nivolumab, Ipilimumab, Nivolumab + Relatlimab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Breast Cancer, Brain Metastases
Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer
Objectives: Primary - Determine the maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLT) of combining lapatinib and temozolomideSecondary - Obtain preliminary information on the clinical anti-tumor…
- Conditions
- Metastatic Breast Cancer, Brain Metastases, HER2 Positive
- Trial name
- LAPTEM (NCT00614978)
- Testing
- lapatinib and temozolomide
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Jules Bordet Institute
Lung Cancer, Metastatic Cancer
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00238251
- Testing
- gefitinib, temozolomide, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 59 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
Multiple trials confirm systemic T-DXd efficacy in HER2+ breast cancer with leptomeningeal/brain metastases, yet median LM survival remains 3-4 months, highlighting unmet needs.
- Trial name
- INOVATE (NCT07134153)
- Testing
- T-DXd
- Where
- 2 sites in China
- Volunteers
- 139 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-small cell lung cancer by…
- Trial name
- NCT04345146
- Testing
- FSRT combined with Bevacizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Metastatic Cancer
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide and vinorelbine in treating patients who…
- Trial name
- NCT00026494
- Testing
- temozolomide, vinorelbine tartrate
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Cancer
Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
Purpose of Study This exploratory clinical study will investigate FMISO (fluoromisonidazole) in patients with (1) newly diagnosed primary malignant brain tumors (WHO [World Health Organization] Grade III or IV glial-based tumors)…
- Trial name
- NCT01246869
- Testing
- [18F]fluoro-2-deoxy-D-glucose (FDG), 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole, [15O]water
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Utah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.